Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528339 | 0.92 | TRPA1 (0.45) | TRPA1MEN1KMT2ATP53HRH3 | |
| SCHEMBL26528088 | 0.91 | TRPA1 (0.38) | TRPA1MEN1KMT2ATP53HRH3 | |
| SCHEMBL26531165 | 0.82 | HRH3 (0.40) | MEN1KMT2ATP53HRH3MAPT | |
| SCHEMBL26531119 | 0.82 | KMT2A (0.46) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL23528311 | 0.78 | SCN1A (0.46) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL26531183 | 0.78 | L3MBTL1 (0.48) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL23528442 | 0.77 | SCN5A (0.48) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL26438304 | 0.76 | MEN1 (0.39) | MEN1KMT2ATP53HRH3MAPT | |
| SCHEMBL23528314 | 0.76 | SCN5A (0.50) | MEN1KMT2ATP53HRH3MAPT | |
| SCHEMBL26528018 | 0.75 | L3MBTL1 (0.48) | MEN1KMT2ATP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | TRPA1 4427/4885MEN1 4467/4885KMT2A 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.